<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02425774</url>
  </required_header>
  <id_info>
    <org_study_id>S56328</org_study_id>
    <nct_id>NCT02425774</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway</brief_title>
  <official_title>Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway: A Potential New Therapeutical Intervention for Postoperative Ileus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

      Prucalopride can mimic electrical stimulation of the abdominal vagus nerve and has an
      anti-inflammatory effect.

      Aims:

      In the present pilot study, the investigators want to evaluate the anti-inflammatory effect
      of prucalopride. The following aims are formulated:

        1. to show that prucalopride has a similar inflammatory effect as abdominal vagus nerve
           stimulation (VNS)

        2. to evaluate whether prucalopride leads to accelerated post-operative recovery
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of pro-inflammatory cytokines in intestinal tissue, serum, peritoneal lavage and supernatant of stimulated whole blood</measure>
    <time_frame>From the date of surgery until the date of lab analysis (up to 6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first flatus</measure>
    <time_frame>From the date of surgery until the date of discharge from the hospital (on average 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tolerance of oral food intake</measure>
    <time_frame>From the date of surgery until the date of discharge from the hospital (on average 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tolerance of oral food intake AND first defecation</measure>
    <time_frame>From the date of surgery until the date of discharge from the hospital (on average 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first defecation</measure>
    <time_frame>From the date of surgery until the date of discharge from the hospital (on average 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal symptoms (nausea, pain, vomiting, bloating)</measure>
    <time_frame>From the date of surgery until the date of discharge from the hospital (on average 14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge from the hospital</measure>
    <time_frame>From the date of surgery until the date of discharge from the hospital (on average 14 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Postoperative Ileus</condition>
  <arm_group>
    <arm_group_label>Sham stimulation + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no stimulation
1 placebo tablet at two different timepoints before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vagus stimulation + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stimulation at the beginning and the end of the surgery
1 placebo tablet at two different timepoints before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prucalopride + sham stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 prucalopride tablet at two different timepoints before surgery
no stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vagus stimulation</intervention_name>
    <arm_group_label>Vagus stimulation + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham stimulation</intervention_name>
    <arm_group_label>Sham stimulation + Placebo</arm_group_label>
    <arm_group_label>Prucalopride + sham stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prucalopride</intervention_name>
    <arm_group_label>Prucalopride + sham stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sham stimulation + Placebo</arm_group_label>
    <arm_group_label>Vagus stimulation + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing partial or full resection of the pancreas due to a benign or
             malignant tumor

        Exclusion Criteria:

          -  adjuvant radiotherapy

          -  evident intra-abdominal inflammation (diagnosed by imaging and/or laboratory results,
             including an abscess or cholecystitis)

          -  chronic pancreatitis

          -  pancreatic polypeptide producing endocrine tumor

          -  American Society of Anesthesiologists physical-health status classification (ASA-PS)&gt;3

          -  Poorly regulated diabetes (&gt;200 mg/dl (=11 mmol/l))
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Boeckxstaens, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Stakenborg, MSc</last_name>
    <phone>+32 16 342883</phone>
    <email>nathalie.stakenborg@med.kuleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim Van Beek, MSc</last_name>
    <phone>+32 16 341326</phone>
    <email>kim.vanbeek@med.kuleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Stakenborg, MSc</last_name>
      <phone>+32 16 342883</phone>
      <email>nathalie.stakenborg@med.kuleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Kim Van Beek, MSc</last_name>
      <phone>+32 16 341326</phone>
      <email>kim.vanbeek@med.kuleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Guy Boeckxstaens, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Kalff JC, Buchholz BM, Eskandari MK, Hierholzer C, Schraut WH, Simmons RL, Bauer AJ. Biphasic response to gut manipulation and temporal correlation of cellular infiltrates and muscle dysfunction in rat. Surgery. 1999 Sep;126(3):498-509.</citation>
    <PMID>10486602</PMID>
  </reference>
  <reference>
    <citation>Kalff JC, Schraut WH, Simmons RL, Bauer AJ. Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postsurgical ileus. Ann Surg. 1998 Nov;228(5):652-63.</citation>
    <PMID>9833803</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Guy Boeckxstaens</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prucalopride</keyword>
  <keyword>Vagus Nerve Stimulation</keyword>
  <keyword>Postoperative Ileus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ileus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Cholinergic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

